GlassScriptPhysician profile
Piipar S Rivera
NPI 1275658007
$7,551.03
in general payments reported to CMS, 2019-2025
28 companies · $853 in 2025
The $853 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,270 · 2022: $1,541 · 2023: $1,504 · 2024: $2,383 · 2025: $853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,745 · Consulting Fee: $800 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,745.29 |
| Consulting Fee | $800.00 |
| Education | $194.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,336.29 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $813.52 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $661.89 | 2021-2025 | Dupixent |
| Janssen Biotech, INC. | $556.37 | 2021-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $508.52 | 2021-2024 | Winlevi, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $477.21 | 2021-2025 | |
| Galderma Laboratories, L.P. | $277.56 | 2021-2025 | Nemluvio, Aklief |
| Lilly USA, LLC | $248.23 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Amgen INC. | $237.06 | 2021-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $222.29 | 2023-2024 | Vtama |
| Almirall LLC | $170.78 | 2021-2023 | Klisyri |
| Genzyme Corporation | $168.81 | 2023-2025 | |
| Verrica Pharmaceuticals INC. | $124.99 | 2023 | Ycanth |
| Epi Health, LLC | $102.81 | 2021-2022 | |
| Ucb, INC. | $85.23 | 2021-2025 | Cimzia, Bimzelx |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $83.50 | 2024 | Zoryve |
| Organon LLC | $81.02 | 2025 | Vtama |
| Merz North America, INC. | $76.13 | 2021-2022 | |
| Incyte Corporation | $71.34 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $48.52 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $46.49 | 2023-2025 | |
| Vyne Pharmaceuticals INC. | $39.65 | 2021 | |
| Leo Pharma INC. | $34.21 | 2021 | |
| Pfizer INC. | $19.57 | 2023 | |
| Biofrontera INC. | $17.89 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Journey Medical Corporation | $13.86 | 2024 | |
| Allergan, INC. | $13.78 | 2021 | |
| Nabriva Therapeutics, Plc | $13.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Piipar Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.